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The role of liver transplantation in 29 patients with 
fulminant and subacute hepatic failure due to a variety 
of different causes was examined by comparing the out-
come and a variety of "hospitalization" variables. Trans-
planted patients (n = 13) were more likely to survive (p 
< 0.05), were younger (p < 0.05) and spent more time 
in the hospital (p < 0.025) than did those who were not 
transplanted (n = 16). Despite spending a much longer 
time in the hospital, transplaRted patients spent less time 
in the intensive care unit (p < 0.05) in coma (p < 0.01) 
and on a respirator (p < 0.01) than did ~hose not trans-
planted. Most importantly, the survival rate for trans-
planted patients was significantly improved (p < 0.05) 
as compared to those not transplanted. We conclude that 
liver transplantation can be applied successfully to the 
difficult clinical problem of fulminant and subacute he-
patic failure. 
Fulminant and subacute hepatic failure are major clin-
- ical problems in hepatology because of the uniformly 
poor prognosis experienced by its victims. Most series 
report mortality figures ranging between 80 to 100% 
with the majority reporting survival rates of only 5 to 
10% (1-6). 
A wide variety of experimental modalities have been 
used in an effort to improve the dismal prognosis of such 
patients. These include charcoal and other resin hemo-
perfusion systems, total body blood exchange techniques, 
temporary liver support using animal organs connected 
in series with the patient and heterotopic liver trans-
plantation (7-15). As yet, none of these methods has 
provided consistent results. Moreover, in most hands, 
the results with these modalities have been little or no 
better than standard medical care provided in an inten-
sive care unit. 
Since February, 1981 until July 1, 1985, we have been 
referred for consideration for orthotopic hepatic trans-
plantation (OLTx) 29 adult patients with acute or sub-
acute hepatic failure. Herein, we report our experience 
with these patients. 
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MATERIALS AND METHODS 
Definitions. For the purpose of this study, fulminant be-
patic failure was defined as the occurrence of severe impairment 
of hepatocellular function progressing to advanced encephalop. 
athy (either advanced Stage 3 or Stage 4) within 8 weeks of 
onset-in an individual without a history or not of evidence of 
previous hepatic disease. Subacute hepatic failure was defined 
as the occurrence of severe irreversible liver failure which 
developed within 8 to 28 weeks from the onset of symptoms in 
an individual without an antecedent. history or evidence of 
chronic liver disease. 
Patients. All patients admitted to either the medical or 
surgical services of the authors of this paper with a diagnosis 
of acute fulminant or subacute hepatic failure in advanced 
Stage III or Stage IV coma have been considered as possible 
candidates for OLTx since February, 1981. Since that time and 
until July 1, 1985, a total of 29 patients have been evaluated 
with these two diagnoses. Of these 29, 11 had fulminant viral 
hepatitis documented by the appropriate viral serologic studies 
and/or a clinical history of a needle stick or other blood 
exposure in the cases of non-A, non-B fulminant hepatitis. 
Nine patients had subacute Wilson's disease documented by 
the presence of Kayser Fleischer rings, an increased urine and 
hepatic content of copper and a reduced serum ceruloplasmin 
level. Nine patients were thought to have fulminant drug or 
toxin-induced hepatotoxicity based upon a clinical history of 
recent drug or toxin exposure, a consistent history of fever and 
rapid onset of hepatotoxicity associated in most cases with an 
eosinophilia and the absence of any serologic or other labora-
tory data to suggest an alternative diagnosis of a recognizable 
viral or metabolic liver disease. 
Diagnostic Evaluation of the Patients. Each patient 
underwent a complete liver transplant evaluation consisting of 
the studies required to identify the specific etiology and the 
severity of their disease, and to recognize and manage any 
complications that may have developed. This evaluation hal 
been described before and has not changed over the 41h years 
which encompass this report (16-18). 
Chart Review and Validation. The charts of the 29 
patients included in this study were reviewed following ~~~ 
discharge or death to obtain the various data herein repo~ 
All records including intensive care unit data sheets, anestbeIIA 
records, operative reports and the medical and surgical progress 
notes were reviewed. In addition, the health status of the 10 
surviving patients has been determined by telephone cont.ad. 
with the patients and their local physicians. val 
Statistical Analysis. All data are reported as mean . • 
ues ± S.E. Statistical differences have been determin~ ~- ,_ 
the Student's t test. Associations have been assessed uS1Dl.WIIfI . 
odds ratio to approximate the relative risk. In this settiDIt t, .. 
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o~ Tx has been considered to be antecedent to the outcome 
I;urvival), and thus the odds ratio has been used to measure 
(he odds in favor of experiencing the outcome (survival). When 
(he confidence interval around the odds ratio excluded unity, 
indicating excess odds in favor, the significance of the associ-
.tion between transplantation and survival was tested using X 2 
119, :W). 
RESULTS 
The mean age of the 29 patients included in this study 
~Das 27.5 ± 2.2 years. Sixteen were female and 13 were 
male. Table 1 shows the individual ages, final diagnoses,' 
t"pe of hepatic failure, time from admission to onset of 
roma and outcome of the 29 patients studied. Table 2 
show~ the liver injury and hematologic parameters of the 
patients studied just before OLTx or at the time of death 
or peak level of abnormality (which ever was greater) if 
OL Tx was not performed. 
Of these 29, only three patients, two females with 
• acute hepatic failure due to recurrent halothane exposure 
and acetaminophen overdose respectively, and a young 
adult male with Wilson's disease, recovered and left the 
hospital alive not having required a liver transplant. Of 
the 26 remaining patients, 13 died waiting to be trans-
planted while 13 others received an OL Tx. Of those 
transplanted, 7 are alive and 6 died, for an overall sur-
vival rate of 10 of 29 (34%). However, it should be noted 
that 55% of those transplanted actually survived (Fig-
ure O. 
In order to determine whether any differences existed 
between those who died waiting to be transplanted and 
those who actually lived long enough to receive a trans-
plant, the age, the time spent in hospital, time spent in 
an intensive care unit, and the time in coma and/or on 
a respirator either prior to transplantation or death as 
well as the amount of blood products consumed by these 
patients were compared (Tables 3 to 5). The patients 
who lived long enough to be transplanted following ad-
mission to the hospital were younger (p < 0.05) and spent 
less time in the intensive care unit (p < 0.05), in coma 
(p < 0.01) and on a respirator (p < 0.01) than did those 
who died waiting to be transplanted (Tables 3 and 4). 
However, because the patients who were transplanted 
survived the early hospital period, as a result of being 
tr8!.!Planted, they spent more total time in the .hospital 
than did those who were not transplanted, most of whom 
TABLE 1. Age, etiology and outcome of the 29 cases of acute and subacute hepatic failure 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
Mean ± S.E. 
Age (yr) 
37 
20 
50 
26 
30 
51 
26 
29 
21 
46 
16 
16 
31 
25 
21 
27 
20 
32 
21 
33 
51 
27 
49 
24 
32 
38 
17 
22 
17 
27.S ± 2.2 
Type of 
DiagnOlli.- hepatic 
failure· 
Non-A, non.-B S 
HBV A 
HBV A 
HBV A 
HBV A 
Non-A, non-B S 
HAV S 
HAV S 
Non-A, non-B S 
HBV S 
Wilson's A 
Wilson's A 
Wilson's A 
Wilson's S 
Wilson's S 
Wilson's S 
Wilson's A 
Wilson's A 
Wilson's A 
Gold A 
Halothane A 
Nitropropane S 
Cimetidine A 
Nitropropane S 
Disulfiram A 
a·Methyldopa A 
Acetaminophen A 
Non-A. non-B S 
Phenytoin S 
"Non-A, non-B == non-A, non-B hepatitis; HBV = hepatitis B virus; HAV == hepatitis A virus. 
, S .. subacute; A - acute. 
Day. in Outeome4 
eoma' 
0 A,T 
3 D,N 
0 D,N 
0 A,T 
0 D,N 
0 D,N 
4 D,N 
0 D,N 
0 A,T 
0 D,N 
2 D,T 
4 A,T 
2 D,N 
1 A,T 
0 D,N 
0 D,N 
0 D,T 
0 A,N 
0 A,T 
7 D,T 
4 A,N 
4 D,T 
0 D,N 
0 D,T 
5 D,N 
2 D,N 
0 A,N 
0 A,T 
0 D,T 
'Values: 0 - <12 hr - 0 days; 1 == >12 but <36 hr - 1 day; 2 - >36 but <60 hr .. 2 days; 3 - >60 but <84 hr .. 3 days; and 4 - >84 but <lOS 
hr. 4 days. 
• A - alive; T - transplanted; D - dead; and N - not transplanted. 
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TABLE 2. Liver injury and hematological parameters of the 29 patients t'..: .' 
... 
Alkaline AST ALT phospbatase (IU/liLer) (IU/liLer) (IU/liLer) 
1 288 456 109 
2 319 340 570 
3 310 350 50 
4 500 620 144 
5 764 622 234 
6 124 53 35 
7 91 25 115 
8 122 62 121 
9 45 50 142 
10 945 801 118 
11 1,526 1,830 170 
12 215 82 875 
13 1,900 2,300 186 
14 140 95 420 
15 149 233 450 
16 140 180 185 
17 235 122 81 
18 965 1,236 320 
19 1,625 1.925 250 
20 444 644 155 
21 321 618 316 
22 3,370 3,500 165 
23 921 227 172 
24 125 135 116 
25 2,295 1,158 173 
26 3,251 3,726 245 
27 152 36 39 
28 187 202 115 
29 151 173 128 
Normal values: <36 <32 <115 
• T/D = total/direct, 
29 PATIENTS 
13 DIED/ 
1 
~P RECOVERED 
WAITING NO TRANSPLANT 
13 RECEIVED A 
TRANSPLANT 
! \ 
6 DIED 7 SURVIVED 
FIG. 1. Schematic outline of the hospital course of the 29 patients 
evaluated. 
(13 of 16 or 81 %) died (Table 3). Despite such a greater 
hospitalization time for those transplanted compared to 
those not transplanted, no significant difference for 
blood product consumption was evident between the four 
groups. 
In order to determine what factors contributed to a 
poor posttransplant outcome, the same variables as well 
as several others known to affect survival following 
OL Tx were compared between those who survived and 
those who did not survive OLTx (Table 4). No statistical 
differences between the two groups were evident for any 
of the 16 separate variables studied. However, a trend 
for a greater amount of time spent in the intensive care 
WhiLe blood cells PIaLelel COllnt -Bilirubin Prolime (XI,OOO (X 100,000 TID" (mgfdl) (llees) cellafmm") cellafmm") 
f 
-29.4/13.1 28 6.0 45 1ii 
44.4/18.4 47 5.3 48 :to. 
32.1/21.9 21 18.9 20 :5 
36.2/18.9 36 14.5 62 
11.3/7.5 14 8.6 179 
51.6/41.6 19 3.3 78 
<, 
5.6/2.9 17 17.6 165 '. 
5.1/2.4 32 8.3 90 
55.0/39.0 27 18.5 58 
16.1/10.2 12 7.4 60 
52.1/39.6 50 14.3 50 
34.6/17.8 18 11.2 72 
56.1/40.2 48 16.1 51 
38.1/11.6 19 10.7 27 
29.1/17.7 25 12.2 23 
9.5/4.4 17 11.8 140 
23.0/8.9 46 6.8 54 
44.0/:rt- 35 67 35 
46.0/40 25 12.3 75 
56.0/41 27 9.4 81 
67.0/57 62 17.1 73 
37.0/11 65 22.1 256 
2.3/1.6 15 2.2 50 
10.5/8.7 18 5.2 84 
20.0/16 25 12.4 150 
15.4/11.4 18 . 7.1 84 
75.0/45 35 18.3 88 
21.0/17.5 22 7.3 75 
36.4/30.1 35 5.9 80 
<1.1/<0.2 10-12 5-10 150-300 
TABLE 3. Hospitalization characteristics of the 29 patients 
studied 
OLT][ OLT][ NoOLT][ NoOLT][ 
survived died aurvived died 
(n= 7) (n=6) (n = 3) (n = 13) 
Age (yr) 21.0 ± 4.0 19.7 ± 4.4 35.3 ± 9.9 34.2 ±3.0 
Time in hospital 12.1 ± 6.9 5.6 ± 2.8 21.7 ± 6.0 3.3 ±0.6 
(days) 
Time in ICU (days) 1.6 ± 0.5 3.1 ± 0.7 5.7 ± 3.2 2.4 ± 0.5 
Time in coma 1.3 ± 0.3 2.4 ± 0.3 3.3 ± 1.9 1.1 ± 0.5 
(days) 
Time on respirator 1.1 ± 0.4 1.7 ± 0.4 1.3 ± 1.3 1.8 ± 0.5 
(days) 
RBC (units) 3.9 ± 0.9 8.6 ± 3.5 4.0 ± 2.2 7.8 ± 1.6 
FFP (units) 15.5 ± 3.5 32.4 ± 15.5 8.0 ± 3.1 17.4 ± 3.2 
The abbreviations used are: ICU = inLensive care unit; RBC .. red ' 
blood ,cells; FFP = fresh frozen plasma. 
unit, time on a respirator and units of blood products 
consumed prior to transplantation was seen for the non-
surviving group. Had the two groups been larger, these 
differeaces may have achieved statistical significance. It 
should be noted, however, that the survivors had a longer 
hospitalization prior to transplant than did those who 
died, suggesting that they may have been less severely ill 
initially. Again, Table 4 shows a trend for greater inten-
sive care unit use, time in coma, total time on a respirator 
and total blood product consumption by those who died 
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. compared to those who survived following OLTx. 
~oreoverI the durati~n of the anhepatic phas~ of the 
. nsplant procedure Itself tended to be longer m those Ira . H di t 
"ho did not. survive. o~everI as a rec conseque~ce 
rtheir survival, the survivors actually spent more time ~ the hospital than did nonsurvivors when all four 
ups are co~pared (Table 5). . 
fI'Orhe immediate cause of death of the 13 patients v.:ho 
died waiting to be transplanted and those who died 
following OLTx are reported in Table 5. 
Figure 2 shows a life table analysis of the 29 patients 
berein reported. The survival rates at time points of 1 
lIlonth or longer from time of hospital admission were 
significantly increased in the transplanted group as com-
pared to those who did not receive a transplant. Specif-
ically. he odds in favor of survival (odds rati?; upper 
95% cunfidence interval; lower 95% confidence mterval; 
and X ~ significance level, respectively) as a result of 
OLTx were increased 7-fold at 1 month (7.33; 38.86, 1.38; 
p <: 0.05) and 5-fold at 6 months (5.06; 15.38, 1.66; P < 
0.05). 
DISCUSSION 
This report clearly documents the poor prognosis of 
patients with acute fulminant and subacute hepatic fail-
ure v'ether treated medically or surgically. It also sup-
ports ,he commonly held idea that youthful persons do 
better than do older patients with such an ·illness. It 
should be noted, however, that only 4 of our 29 subjects 
were less than, 20 years of age, the usual cut-off age cited 
TABLE 4. Characteristics of 13 transplanted patients 
Characteristic Survivol'll NODsurvivol'll (0 = 7) (0 = 6) 
Agl' I' 'I 21.0 ± 4.0 19.7 ± 4.4 
Timt· ; n hospital prior to 12.1 ± 6.9 4.6 ± 2.6 
OLTx (days) 
Time in leU prior to OLTx 0.6 ± 0.5 1.1 ± 0.5 
(days) 
Time in coma prior to OL Tx 0.3 ± 0.3 0.4 ± 0.3 
(days) 
Time on respirator prior to 0.1 ± 0.2 0.7 ± 0.5 
OLTx (days) 
Units of RBC used prior to 1.9 ± 0.8 4.6 ± 2.5 
OLTx 
Unit, of FFP used prior to 10.5 ± 3.3 22.4 ± 12.5 
O:.Tx 
qot~l time in hospital (days) 67.8 ± 19.4 26.0 ± 13.7 
Total time in ICU (days) 2.8 ± 0.8 14.1 ± 5.9 
Total time in coma (days) 0.5 ± 0.4 7.3 ± 4.7 
Total time on respirator 1.8 ± 0.4 9.9 ± 4.8 
(days) 
Time for hepatectomy (min) 221.3 ± 42.5 168.6 ± 41.8 
A hepatic time (min) 64.6 ± 11.8 96.7 ± 21.8 
Implantation time (min) 262.8 ± 50.5 320.6 ± 84.8 
Total units RBC (per hospi· 13.8 ± 3.5 32.2 ± 10.5 
t!llizationl 
T"t ,I units FFP (per hospi· 22.4 ± 5.6 41.1 ± 14.1 
liliizationl 
Values are mean ± S.E. 
The abbreviations used are: lCU = intensive care unit; RBC = red 
blood cells; FFP = fresh frozen plasma. 
TABLE 5. Cause of death observed in the 19 patients who died 
I. Those not transplanted (n = 13) 
Hepatic failure 
Cerebral edema 1 
Hepatorenal syndrome 4 
Hemorrhagic pancreatitis 1 
Bacterial sepsis 3 
Gastrointestinal bleeding 2 
Cerebral hemorrhage 2 
II. Those transplanted (n = 6) 
Fungemia 
Renal failure 1 
Subarachnoid hemorrhage 1 
Bacterial sepsis 3 
for individuals having a better prognosis with fulminant 
or subacute hepatic failure. Moreover, two of these four 
died while one recovered without OLTx (Table 1). Thus, 
we do not believe that the younger mean age of the 
transplanted patients accounts for their greater survival. 
Most importantly, this report demonstrates that the 
shofter the time the patient is in coma and/or on a 
respirator, the better the overall prognosis of the patient. 
This observation is consistent with earlier reports of 
poorer posttransplant survival in patients hospitalized 
within intensive care units and those on respirators prior 
to OLTx (21). Finally, the present data document that 
liver transplantation alters the natural history of pa-
tients in advanced Stage III or IV hepatic coma due to 
acute fulminant and subacute hepatic failure by improv-
ing survival and changir.g the causes of death in those 
who ultimately die. Specifically, those who die prior to 
transplantation do so because of hepatic failure or one 
of it's several associated complications (Table 5), while 
those who die after transplantation do so primarily be-
cause of either bacterial or fungal sepsis or renal failure, 
both of which are probably related to the use of cyclo-
sporin-prednisone immunosuppression. The causes of 
death following transplantation observed in the patients 
herein reported do not differ from those of patients 
transplanted for the more usual indications for OL Tx 
reported previously (22). 
Nonetheless, the present data clearly document a 2.8-
fold increased survival rate at 6 months for those patients 
who were transplanted as compared to those who were 
not. Data concerning the long-term survival of these 
patients are currently not available. However, as one 
would not expect the original toxic or metabolic liver 
disease to reoccur in the patients with such diseases 
originally, it is not unreasonable to believe that their 
long-term survival should be no different from that of 
individuals surviving OL Tx performed for other indica-
tions. These data suggest that the survival curve is nearly 
flat 3 months after OLTx and remains so for approxi-
mately 6 years, the limits provided by the currently 
available experience for the large number of patients 
surviving OLTx. It is of some interest to note moreover 
that the single survivor of acute fulminant type B hepa-
titis became hepatitis B surface antibody-positive post-
operatively and is currently working full time free of any 
clinical or biochemical evidence of liver disease. 
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FIG. 2. Actuarial life table analysis of the 29 patients evaluated with acute fulminant and subacute hepatic failure divided into two ~ 
those transplanted (closed squares) and those not transplanted (open CircfepFK~I 
Finally, it should be noted that liver failure, particu-
larly its fulminant and subacute hepatic forms, is not a 
homogenous condition and that survival is known to be 
influenced by the underlying etiology (23, 24). In fact, 
the mix of patients herein reported is somewhat unusual, 
with 9 of the 29 having had fulminant Wilson's disease. 
It should be noted in addition, however, that with the 
exception of this report, no case of fulminant Wilson's 
disease has been reported to survive to date without 
OLTx. It should also be noted that only those who use 
less restrictive definitions of fulminant and subacute 
hepatic failure (e.g., not requiring the obligate presence 
of deep Stage 3 or Stage 4 coma) have reported survival 
rates of between 33 and 70%, which are comparable to 
what we have found in advanced stages of hepatic en-
cephalopathy (1, 3, 5,10,23-28). Clearly, the role of liver 
transplantation in patients having less severe fulminant 
or subacute hepatic dysfunction but not in advanced 
Grade 3 or 4 hepatic encephalopathy but rather in Stage 
2 and early Stage 3 remains to be determined. The 
current data suggest, however, that once an advanced 
stage of hepatic encephalopathy is reached, that liver 
transplantation improves survival in this particularly ill 
subset of patients with fulminant and subacute hepatic 
failure. This is particularly evident when one considers 
that spontaneous recovery, as evidenced by a return of 
consciousness, removed patients herein reported from 
the active transplant candidate list and thereby actually 
prejudices the data for survival in favor of the group not 
transplanted. 
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